Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

721 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, Mesa R, Rampal RK, Gerds AT, Yacoub A, Pettit K, Talpaz M, Komrokji R, Kremyanskaya M, Gonzalez A, Fabris F, Johnson K, Dougherty M, McGovern E, Arango Ossa J, Domenico D, Farnoud N, Weinberg RS, Kong A, Najfeld V, Vannucchi AM, Arciprete F, Zingariello M, Falchi M, Salama ME, Mead-Harvey C, Dueck A, Varricchio L, Hoffman R. Mascarenhas J, et al. Among authors: dougherty m. Clin Cancer Res. 2023 Sep 15;29(18):3622-3632. doi: 10.1158/1078-0432.CCR-23-0276. Clin Cancer Res. 2023. PMID: 37439808 Free PMC article. Clinical Trial.
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.
Feld J, Tremblay D, Dougherty M, Czaplinska T, Sanchez G, Brady C, Kremyanskaya M, Bar-Natan M, Keyzner A, Marcellino BK, Gabrilove J, Navada SC, Silverman LR, El Jamal SM, Mascarenhas J, Shih AH. Feld J, et al. Among authors: dougherty m. Hemasphere. 2021 Mar 9;5(4):e549. doi: 10.1097/HS9.0000000000000549. eCollection 2021 Apr. Hemasphere. 2021. PMID: 33718803 Free PMC article.
PD-1 inhibition in advanced myeloproliferative neoplasms.
Hobbs G, Cimen Bozkus C, Moshier E, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster JE, Som T, Macrae M, Marble H, Salama M, El Jamal SM, Zubizarreta N, Wadleigh M, Stone R, Bhardwaj N, Iancu-Rubin C, Mascarenhas J. Hobbs G, et al. Among authors: dougherty m. Blood Adv. 2021 Dec 14;5(23):5086-5097. doi: 10.1182/bloodadvances.2021005491. Blood Adv. 2021. PMID: 34581778 Free PMC article.
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.
Tremblay D, Dougherty M, Mascarenhas J, Gallagher EJ. Tremblay D, et al. Among authors: dougherty m. Front Endocrinol (Lausanne). 2023 Jun 29;14:1141029. doi: 10.3389/fendo.2023.1141029. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37455900 Free PMC article. Review.
Correction: A Mixed-Methods Approach for Evaluating Implementation Processes and Program Costs for a Hypertension Management Program Implemented in a Federally Qualified Health Center.
Tucker-Brown A, Spafford M, Wittenborn J, Rein D, Marshall A, Beasley KL, Vaughan M, Nelson N, Dougherty M, Ahn R. Tucker-Brown A, et al. Among authors: dougherty m. Prev Sci. 2024 Mar 20. doi: 10.1007/s11121-024-01670-1. Online ahead of print. Prev Sci. 2024. PMID: 38507040 No abstract available.
721 results